Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew Kent
Institution:
University of Colorado Anschutz
Observed institution:
University of Colorado Anschutz
ORCID:
0000-0001-5523-6561
Observed ORCID:
0000-0001-5523-6561
OpenAlex ID:
A5125984305
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy
2026
·
Justin Watts
, Ellen Madarang
, et al.
·
Haematologica
·
10
PDF
A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia
2026
·
Maria L. Amaya
, Diana Abbott
, et al.
·
Blood Advances
·
1
PDF
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
2026
·
Michael K. Jones
, Jesse Sanchez
, et al.
·
American Journal of Hematology
Show more works
View as search
Works count:
3
Citation count:
11
H-index:
1
I10-index:
1
Year
Topic
Type